Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 82 clinical trials
Featured trial
A Study Evaluating Safety and Tolerability and Pharmacokinetics of Navitoclax Monotherapy and in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasm

neoplasm (MPN) or chronic myelomonocytic leukemia (CMML).

essential thrombocythemia
polycythemia
myelofibrosis
ruxolitinib
bone marrow procedure
  • 50 views
  • 23 Oct, 2022
  • 36 locations
Azacitidine and Homoharringtonine in JMML

Juvenile myelomonocytic leukemia (JMML) has a poor prognosis in general, with hematopoietic stem cell transplant (HSCT) remaining the standard of care for cure. Azacitidine and homoharringtonine

refractory acute myeloid leukemia (aml)
azacitidine
myeloid leukemia
  • 0 views
  • 25 Jan, 2021
  • 1 location
A Study to Evaluate MK-0482 for Relapsed/Refractory Acute Myeloid Leukemia (AML) or Chronic Myelomonocytic Leukemia (CMML) (MK-0482-002)

The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and recommended Phase 2 dose (RP2D) of MK-0482. There are 2 parts of this study. Part 1 is a dose escalation which will follow an accelerated titration design (ATD). Part 2 is a dose expansion in the …

  • 1 views
  • 04 Oct, 2022
  • 2 locations
Study of Oral LY3410738 in Patients With Advanced Hematologic Malignancies With IDH1 or IDH2 Mutations

This is an open-label, multi-center Phase 1 study of LY3410738, an oral, covalent IDH inhibitor, in patients with IDH1 and/or IDH2-mutant advanced hematologic malignancies who have received standard therapy

hematologic malignancy
IDH2
blast cells
  • 0 views
  • 07 Oct, 2022
  • 36 locations
GvHD Prophylaxis in Unrelated Donor HCT: Randomized Trial Comparing PTCY Versus ATG (GRAPPA)

Post-transplantation cyclophosphamide (PTCY) has become increasingly popular in the haploidentical HCT setting because it overcomes the HLA-mismatch barrier and levels GVHD risk. This advantage may also prove useful in the context of unrelated donor (UD) transplantation. GVHD prophylaxis for matched unrelated donor hematopoietic cell transplantation (alloHCT) in Europe is mainly …

  • 0 views
  • 04 Oct, 2022
  • 12 locations
Canakinumab and Anacitidine for the Treatment of Low or Intermediate Risk Myelodysplastic Syndrome and Chronic Myelomonocytic Leukemia

This phase II trial studies how well canakinumab works for the treatment of low- or intermediate-risk myelodysplastic syndrome or chronic myelomonocytic leukemia. Canakinumab is a monoclonal

sgi-110
astx727
lenalidomide
azacitidine
decitabine
  • 0 views
  • 08 Jul, 2022
  • 1 location
Venetoclax in Combination With ASTX727 for the Treatment of Treatment-Naive High-Risk Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia

or chronic myelomonocytic leukemia who have not received prior treatment (treatment-naive). Chemotherapy drugs, such as venetoclax, cedazuridine, and decitabine, work in different ways to stop the

cancer
hydroxyurea
myelomonocytic leukemia
leukemia
decitabine
  • 0 views
  • 04 Oct, 2022
  • 1 location
A Study of H3B-8800 (RVT-2001) in Participants With Myelodysplastic Syndromes, Acute Myeloid Leukemia, and Chronic Myelomonocytic Leukemia

Syndromes, Acute Myeloid Leukemia, and Chronic Myelomonocytic Leukemia

myelodysplastic syndromes
lenalidomide
decitabine
azacitidine
chronic myelomonocytic leukemia
  • 0 views
  • 19 Apr, 2022
  • 7 locations
A Phase 2 Study of the MEK Inhibitor Trametinib (NSC# 763093) in Children With Relapsed or Refractory Juvenile Myelomonocytic Leukemia

This phase II trial studies how well trametinib works in treating patients with juvenile myelomonocytic leukemia that has come back (relapsed) or does not respond to treatment (refractory

tumor cells
biologic agent
measurable disease
total serum bilirubin
ejection fraction
  • 254 views
  • 27 Oct, 2022
  • 39 locations
Enasidenib in MDS &Non-proliferative Chronic Myelomonocytic Leukemia w/o IDH2 Mutation

myelodysplastic syndrome (MDS) or nonproliferative chronic myelomonocytic leukemia (CMML) without a mutation in isocitrate dehydrogenase type 2 (IDH2 wildtype). Other objectives include assessment of improvements

anemia
  • 0 views
  • 08 Jun, 2022
  • 1 location